BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 33147338)

  • 1. Whole transcriptome sequencing detects a large number of novel fusion transcripts in patients with AML and MDS.
    Stengel A; Shahswar R; Haferlach T; Walter W; Hutter S; Meggendorfer M; Kern W; Haferlach C
    Blood Adv; 2020 Nov; 4(21):5393-5401. PubMed ID: 33147338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndromes are associated with complex karyotype, monosomal karyotype,
    Wang N; Yuan L; Jing Y; Fan K; Jin H; Lv C; Wang L; Yu L
    Leuk Lymphoma; 2021 Oct; 62(10):2466-2474. PubMed ID: 33904352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
    Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of chromosome karyotype between myelodysplastic syndrome and acute leukemia patients confirmed at the same period].
    Jiang M; Wen BZ; Li L; Chen S; Cheng H; Hao JP; Chen R; Wang L; Zhao F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):387-92. PubMed ID: 24763010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Niparuck P; Police P; Noikongdee P; Siriputtanapong K; Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Siriboonpiputtana T
    Diagn Pathol; 2021 Oct; 16(1):100. PubMed ID: 34717674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
    Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
    Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Nardi V; Hasserjian RP
    Surg Pathol Clin; 2016 Mar; 9(1):143-63. PubMed ID: 26940274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
    Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
    Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.
    Kohlmann A; Bacher U; Schnittger S; Haferlach T
    Leuk Lymphoma; 2014 Aug; 55(8):1725-34. PubMed ID: 24144312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients.
    Rossi G; Pelizzari AM; Bellotti D; Tonelli M; Barlati S
    Leukemia; 2000 Apr; 14(4):636-41. PubMed ID: 10764149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Grob T; Al Hinai ASA; Sanders MA; Kavelaars FG; Rijken M; Gradowska PL; Biemond BJ; Breems DA; Maertens J; van Marwijk Kooy M; Pabst T; de Weerdt O; Ossenkoppele GJ; van de Loosdrecht AA; Huls GA; Cornelissen JJ; Beverloo HB; Löwenberg B; Jongen-Lavrencic M; Valk PJM
    Blood; 2022 Apr; 139(15):2347-2354. PubMed ID: 35108372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application of Next Generation Sequencing for AML/MDS Diagnosis and Treatment].
    Cheng HC; Liu SW; Liu Y; Zhao XF; Li W; Qiu L; Ma J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1631-1635. PubMed ID: 29262888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.
    Weinberg OK; Siddon A; Madanat YF; Gagan J; Arber DA; Dal Cin P; Narayanan D; Ouseph MM; Kurzer JH; Hasserjian RP
    Blood Adv; 2022 May; 6(9):2847-2853. PubMed ID: 35073573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelodysplastic Syndrome with t(1;14),t(1;17),t(1;19) Transforms to AML-M5: A Case Report and Literature Review.
    Zhang H; Li G; Chang J; Wang H
    Ann Clin Lab Sci; 2020 May; 50(3):401-403. PubMed ID: 32581034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
    J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute erythroid leukemia is enriched in NUP98 fusions: a report from the Children's Oncology Group.
    Chisholm KM; Heerema-McKenney AE; Choi JK; Smith J; Ries RE; Hirsch BA; Raimondi SC; Alonzo TA; Wang YC; Aplenc R; Sung L; Gamis AS; Meshinchi S; Kahwash SB
    Blood Adv; 2020 Dec; 4(23):6000-6008. PubMed ID: 33284945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique.
    Owattanapanich W; Herzig J; Jahn N; Panina E; Ruchutrakool T; Kungwankiattichai S; Issaragrisil S; Döhner H; Döhner K
    Ann Hematol; 2021 Aug; 100(8):1983-1993. PubMed ID: 33839881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases.
    Stengel A; Kern W; Haferlach T; Meggendorfer M; Fasan A; Haferlach C
    Leukemia; 2017 Mar; 31(3):705-711. PubMed ID: 27680515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic landscape of TP53-mutated myeloid malignancies.
    Abel HJ; Oetjen KA; Miller CA; Ramakrishnan SM; Day RB; Helton NM; Fronick CC; Fulton RS; Heath SE; Tarnawsky SP; Nonavinkere Srivatsan S; Duncavage EJ; Schroeder MC; Payton JE; Spencer DH; Walter MJ; Westervelt P; DiPersio JF; Ley TJ; Link DC
    Blood Adv; 2023 Aug; 7(16):4586-4598. PubMed ID: 37339484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.